Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

Name: Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.
Published: 2012
License: Public Domain

Sinocelltech Ltd. · 2012

ClinicalTrials.gov · Datasets · License: Public Domain · 2012

Open Source ↗

safety

b-cell non hodgkin's lymphoma, chimeric anti-cd20 monoclonal antibody(sct400), escalating doses, safety, pharmacokinetics and pharmacodynamics, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

Related documents